Elevation Oncology is developing cancer therapies to target solid tumors. Cancers are characterized by uncontrolled growth. By understanding the drivers of this growth, Elevation hopes to find the best way to treat it. Elevation breaks this down into four steps: [1] mapping the terrain through genomic testing, [2] surveying the peaks to identify targetable drivers, [3] blazing the path to create efficient and selective drugs and [4] building a novel selective cancer therapy pipeline. Elevation’s lead candidate, EO-3021, targets Claudin18.2 - a target Elevation has identified as being expressed across several types of solid tumors. EO-3021 is an antibody-drug conjugate that is currently being tested in Phase 1 clinical trials.

Elevation Oncology

Founded: 2019
Location: New York, NY
Employee range: 50 - 200
Clinical stage: Clin2
Therapy area: Solid tumors
Drug types: ONC
Lead product: Seribantumab
Funding: $50M stock Jun 2023; $100M IPO Jul 2021; $65M B Nov 2020; $32.5M A Jul 2020

Drug notes:

About:

Jobs: